ORGANIZATION

3 Indicted Wholesalers Now Barred from National Hospital Organization Bids, Others Following Suit

December 21, 2020

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The National Hospital Organization, which has 140 hospitals under its umbrella, has suspended three major wholesalers indicted over bid-rigging charges from its bidding process for one year starting from December 18. Alfresa, Suzuken, and Toho Pharmaceutical and seven employees at…

To read the full story

3 Indicted Wholesalers Barred from JCHO/NHO Bids, but Can Sell Single-Channel Drugs to Ensure Access
January 26, 2021
3 Indicted Wholesalers Barred from JCHO Bids for 2 Years: Bid-Rigging Scandal
December 14, 2020

ORGANIZATION

Society Envisions 1 Trillion Yen in Overseas Sales for Japan’s Off-Patent Drug Sector by 2040
June 9, 2026
Employees of 9 Pharma Firms Team Up for LGBTQ+ Inclusion
June 8, 2026
Time Ripe for Debate on Drug Spending Macroeconomic Indexing: INES
June 3, 2026
Labor Group Urges MHLW to Support Pharma Talent Development
June 3, 2026
Labor Group Urges Govt to View Pharma as Investment, Not Cost
June 1, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Are Technical Discussions Enough for Japan’s CEA System?

By Ken Yoshino

Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…